 | Up a level |
Journal Article
Henkemeier, U., Alten, R., Bannert, B., Baraliakos, X., Behrens, F., Heldmann, F., Kiltz, U., Koehm, M., Koenig, R., Leipe, J., Mueller-Ladner, U., Rech, J., Riechers, E., Rubbert-Roth, A., Schmidt, R. E., Schulze-Koops, H., Specker, C., Tausche, A. -K, Wassenberg, S., Witt, M., Witte, T., Zernicke, J. and Burkhardt, H. (2016). Do we still need clinical studies in rheumatology? Z. Rheumatol., 75 (1). S. 4 - 11. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1435-1250
Hunzelmann, N., Moinzadeh, P., Riemekasten, G., Becker, M., Kreuter, A., Mueller-Ladner, U., Meier, F., Wozel, G., Melchers, I., Srdy, M., Sunderkoetter, C., Herrgott, I., Graefenstein, K., Zeidler, G., Fierlbeck, G., Pfeiffer, C., Worm, M., Lee, H., Burkhardt, H., Koehm, M., Henes, J., Mensing, H., Kuhr, K. and Krieg, T. (2015). Low risk for digital ulcer development in SSc patients with increasing disease duration and lack of Scl-70 autoantibodies. Exp. Dermatol., 24 (3). S. E11 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Hunzelmann, N., Moinzadeh, P., Riemekasten, G., Becker, M., Kreuter, A., Mueller-Ladner, U., Meier, F., Wozel, G., Melchers, I., Srdy, M., Sunderkoetter, C., Herrgott, I., Graefenstein, K., Zeidler, G., Fierlbeck, G., Pfeiffer, C., Worm, M., Lee, H., Burkhardt, H., Koehm, M., Henes, J., Mensing, H., Kuhr, K. and Krieg, T. (2015). Low risk for digital ulcer development in SSc patients with increasing disease duration and lack of Scl-70 autoantibodies. Exp. Dermatol., 24 (3). S. E11 - 1. HOBOKEN: WILEY-BLACKWELL. ISSN 1600-0625
Hunzelmann, N., Riemekasten, G., Becker, M. O., Moinzadeh, P., Kreuter, A., Melchers, I., Mueller-Ladner, U., Meier, F., Worm, M., Lee, H., Herrgott, I., Pfeiffer, C., Fierlbeck, G., Henes, J., Juche, A., Zeidler, G., Mensing, H., Guenther, C., Sardy, M., Burkhardt, H., Koehm, M., Kuhr, K., Krieg, T. and Sunderkoetter, C. (2016). The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase-1 antibodies. Br. J. Dermatol., 174 (6). S. 1384 - 1388. HOBOKEN: WILEY. ISSN 1365-2133
Hunzelmann, Nicolas, Riemekasten, G., Becker, M.O., Moinzadeh, Pia 
ORCID: 0000-0002-8784-8615, Kreuter, Alexander ORCID: 0000-0003-2275-499X, Melchers, I., Müller‐Ladner, Ulf, Meier, Friedegund ORCID: 0000-0003-4340-9706, Worm, Margitta ORCID: 0000-0002-3449-1245, Lee, H., Herrgott, I., Pfeiffer, C., Fierlbeck, G., Henes, J., Juche, A., Zeidler, G., Mensing, H., Günther, C., Sardy, Miklos ORCID: 0000-0003-4306-5093, Burkhardt, H., Koehm, M., Kuhr, K., Krieg, Thomas M. ORCID: 0000-0001-5616-8476 and Sunderkötter, C.
(2016).
The Predict Study: low risk for digital ulcer development in patients with systemic sclerosis with increasing disease duration and lack of topoisomerase‐1 antibodies.
British Journal of Dermatology, 174 (6).
pp. 1384-1387.
Oxford University Press.
ISSN 0007-0963
Koehm, M., Rossmanith, T., Dauth, S., Alten, R., Aringer, M., Backhaus, M., Burmester, G., Feist, E., Kellner, H., Krueger, K., Mueller-Ladner, U., Rubbert-Roth, A., Tony, H-P., Wassenberg, S., Burkhardt, H. and Behrens, F. (2017). IMPACT OF RITUXIMAB IN COMBINATION WITH LEFLUNOMIDE AND RITUXIMAB RETREATMENT WITH TWO DIFFERENT DOSAGES ON PATIENT-REPORTED OUTCOMES: RESULTS FROM A MULTICENTER RANDOMIZED PLACEBO CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL IN ACTIVE RHEUMATOID ARTHRITIS (AMARA-STUDY). Ann. Rheum. Dis., 76. S. 565 - 566. LONDON: BMJ PUBLISHING GROUP. ISSN 1468-2060
Koehm, M., Rossmanith, T., Foldenauer, A. C., Kellner, H., Kiltz, U., Rech, J., Burmester, G. R., Kofler, D. M., Brandt-Juergens, J., Jonetzko, C., Burkhardt, H. and Behrens, F. (2022). EFFICACY OF UST IN ACTIVE PSA IS INDEPENDENT FROM CONCOMITANT MTX USE, EVEN IN PATIENTS WITH MORE SEVERE SKIN PSORIASIS: SUBGROUP ANALYSIS FROM A RANDOMIZED PLACEBO-CONTROLLED INVESTIGATOR INITIATED CLINICAL TRIAL. Ann. Rheum. Dis., 81. S. 850 - 852. LONDON: BMJ PUBLISHING GROUP. ISSN 1468-2060